Paratek says may file marketing application for antibiotic in early ’18
Paratek Pharmaceuticals Inc. PRTK, -3.38% shares surged in the extended session Monday after the small biotech company reported a late-stage study of its bacterial pneumonia drug met its endpoints. Paratek shares jumped 30% to $24.10 after hours, following a brief trading halt. The company said its community-acquired bacterial pneumonia antibiotic omadacycline was not inferior to the antibiotic moxifloxacin. Paratek said it plans to file a marketing application with the Food and Drug Administration as early as the first quarter of 2018.